IMR Press / FBS / Volume 2 / Issue 1 / DOI: 10.2741/S53

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article

Chemokines and chemokine receptors in arthritis

Show Less
1 Division of Rheumatology, Third Department of Medicine, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary, Europe
2 Veterans' Administration, Ann Arbor Healthcare System, Ann Arbor, Michigan, USA
3 University of Michigan Health System, Department of Internal Medicine, Division of Rheumatology, Ann Arbor, Michigan, USA

*Author to whom correspondence should be addressed.

Academic Editor: Arpad Barabas

Front. Biosci. (Schol Ed) 2010, 2(1), 153–167; https://doi.org/10.2741/S53
Published: 1 January 2010
(This article belongs to the Special Issue Autoimmune diseases: their etiology, pathogenesis and treatment)
Abstract

Chemokines are involved in leukocyte recruitment to inflammatory sites, such as the synovial tissue in rheumatoid arthritis (RA). There is a structural and a functional classification of chemokines. The former includes four groups: CXC, CC, C and CX3C chemokines. Chemokines may also be either inflammatory or homeostatic, however, these functions often overlap. Anti-chemokine and anti-chemokine receptor targeting may be therapeutically used in the future biological therapy of arthritis. Most data in this field have been obtained from animal models of arthritis as only very few human RA trials have been completed. However, it is very likely that various specific chemokine and chemokine receptor antagonists will be developed and administered to RA patients.

Share
Back to top